Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin reuptake inhibitor fluoxetine in rats

Frontiers in Behavioral Neuroscience

Volumn , Issue DECEMBER, 2011, Pages

  Ravinder, Shilpa ^a   Pillai, Anup G ^a,b   Chattarji, Sumantra ^a  

^a TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amygdala; Anxiety; Dendritic spines; Fluoxetine; Neuronal excitability; SSRI

Indexed keywords

EID: 84871382316     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2011.00088     Document Type: Article

References (77)

1. Amano, T., Unal, C. T., and Pare, D. (2010). Synaptic correlates of fear extinction in the amygdala. Nat. Neurosci. 13, 489-494.
2. Anand, A., and Shekhar, A. (2003). Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala. Ann. N. Y. Acad. Sci. 985, 370-388.
3. Bagdy, G., Graf, M., Anheuer, Z. E., Modos, E. A., and Kantor, S. (2001). Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 4, 399-408.
4. Belzung, C., Le Guisquet, A. M., Barreau, S., and Calatayud, F. (2001). An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav. Pharmacol. 12, 151-162.
5. Bennur, S., Shankaranarayana Rao, B. S., Pawlak, R., Strickland, S., Mcewen, B. S., and Chattarji, S. (2007). Stress-induced spine loss in the medial amygdala is mediated by tissue-plasminogen activator. Neuroscience 144, 8-16.
6. Bezchlibnyk-Butler, K., Aleksic, I., and Kennedy, S. H. (2000). Citalopram-a review of pharmacological and clinical effects. J. Psychiatry Neurosci. 25, 241-254.
7. Bianchi, M. T. (2008). Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy. Med. Hypotheses 70, 951-956.
8. Bodnoff, S. R., Suranyicadotte, B., Quirion, R., and Meaney, M. J. (1989). A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety Psychopharmacology (Berl.) 97, 277-279.
9. Bondareff, W., Alpert, M., Friedhoff, A. J., Richter, E. M., Clary, C. M., and Batzar, E. (2000). Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am. J. Psychiatry 157, 729-736.
10. Bosker, F. J., Cremers, T. I., Jongsma, M. E., Westerink, B. H., Wikstrom, H. V., and Den Boer, J. A. (2001). Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J. Neurochem. 76, 1645-1653.
11. Burghardt, N. S., Bush, D. E. A., Mcewen, B. S., and Ledoux, J. E. (2007). Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT2C receptor antagonist. Biol. Psychiatry 62, 1111-1118.
12. Burghardt, N. S., Sullivan, G. M., Mcewen, B. S., Gorman, J. M., and Ledoux, J. E. (2004). The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol. Psychiatry 55, 1171-1178.
13. Choi, B. H., Choi, J. S., Yoon, S. H., Rhie, D. J., Min, D. S., Jo, Y. H., Kim, M. S., and Hahn, S. J. (2001). Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology 41, 443-453.
14. Choi, J. S., Choi, B. H., Ahn, H. S., Kim, M. J., Han, T. H., Rhie, D. J., Yoon, S. H., Jo, Y. H., Kim, M. S., and Hahn, S. J. (2004). Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons. Brain Res. 1018, 201-207.
15. Choi, J. S., Hahn, S. J., Rhie, D. J., Yoon, S. H., Jo, Y. H., and Kim, M. S. (1999). Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J. Pharmacol. Exp. Ther. 291, 1-6.
16. Collins, D. R., and Pare, D. (2000). Differential fear conditioning induces reciprocal changes in the sensory responses of lateral amygdala neurons to the CS(+) and CS(-). Learn. Mem. 7, 97-103.
17. Davis, M., Walker, D. L., Miles, L., and Grillon, C. (2010). Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35, 105-135.
18. Dekeyne, A., Denorme, B., Monneyron, S., and Millan, M. J. (2000). Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology 39, 1114-1117.
19. Del-Ben, C. M., Deakin, J. F. W., Mckie, S., Delvai, N. A., Williams, S. R., Elliott, R., Dolan, M., and Anderson, I. M. (2005). The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an fMRI study. Neuropsychopharmacology 30, 1724-1734.
20. Duvarci, S., and Pare, D. (2007). Glucocorticoids enhance the excitability of principal basolateral amygdala neurons. J. Neurosci. 27, 4482-4491.
21. Ehrlich, I., Humeau, Y., Grenier, F., Ciocchi, S., Herry, C., and Luthi, A. (2009). Amygdala inhibitory circuits and the control of fear memory. Neuron 62, 757-771.
22. Feldman, M. L., and Peters, A. (1979). A technique for estimating total spine numbers on Golgi-impregnated dendrites. J. Comp. Neurol. 188, 527-542.
23. Fergusson, D., Doucette, S., Cranley, K., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., and Hutton, B. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br. Med. J. 330, 396-399.
24. Goldstein, B. J., and Goodnick, P. J. (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol. 12, S55-S87.
25. Gorman, J. M. (2003). Treating generalized anxiety disorder. J. Clin. Psychiatry 64, 24-29.
26. Gorman, J. M., Liebowitz, M. R., Fyer, A. J., Goetz, D., Campeas, R. B., Fyer, M. R., Davies, S. O., and Klein, D. F. (1987). An open trial of fluoxetine in the treatment of panic attacks. J. Clin. Psychopharmacol. 7, 329-332.
27. Govindarajan, A., Rao, B. S. S., Nair, D., Trinh, M., Mawjee, N., Tonegawa, S., and Chattarji, S. (2006). Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc. Natl. Acad. Sci. U.S.A. 103, 13208-13213.
28. Griebel, G., Moreau, J. L., Jenck, F., Misslin, R., and Martin, J. R. (1994). Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology (Berl.) 113, 463-470.
29. Grillon, C. (2008). Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology (Berl.) 199, 421-437.
30. Hahn, S. J., Choi, J. S., Rhie, D. J., Oh, C. S., Jo, Y. H., and Kim, M. S. (1999). Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells. Eur. J. Pharmacol. 367, 113-118.
31. Hammack, S. E., Guo, J. D., Hazra, R., Dabrowska, J., Myers, K. M., and Rainnie, D. G. (2009). The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1309-1320.
32. Hasler, G., Drevets, W. C., Manji, H. K., and Charney, D. S. (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology 29, 1765-1781.
33. Hasler, G., and Northoff, G. (2011). Discovering imaging endophenotypes for major depression. Mol. Psychiatry 16, 604-619.
34. Hofer, S. B., and Bonhoeffer, T. (2010). Dendritic spines: the stuff that memories are made of? Curr. Biol. 20, R157-R159.
35. Horner, C. H., and Arbuthnott, E. (1991). Methods of estimation of spine density-are spines evenly distributed throughout the dendritic field? J. Anat. 177, 179-184.
36. Karson, C. N., Newton, J. E., Livingston, R., Jolly, J. B., Cooper, T. B., Sprigg, J., and Komoroski, R. A. (1993). Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5, 322-329.
37. Karst, H., Berger, S., Erdmann, G., Schutz, G., and Joels, M. (2010). Metaplasticity of amygdalar responses to the stress hormone corticosterone. Proc. Natl. Acad. Sci. U.S.A. 107, 14449-14454.
38. Kennard, L. E., Chumbley, J. R., Ranatunga, K. M., Armstrong, S. J., Veale, E. L., and Mathie, A. (2005). Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 144, 821-829.
39. Kent, J. M., Coplan, J. D., and Gorman, J. M. (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry 44, 812-824.
40. Kobayashi, T., Washiyama, K., and Ikeda, K. (2004). Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology 29, 1841-1851.
41. Koks, S., Beljajev, S., Koovit, I., Abramov, U., Bourin, M., and Vasar, E. (2001). 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berl.) 153, 365-372.
42. Kurt, M., Arik, A. C., and Celik, S. (2000). The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J. Basic. Clin. Physiol. Pharmacol. 11, 173-180.
43. LeDoux, J. E. (2000). Emotion circuits in the brain. Annu. Rev. Neurosci. 23, 155-184.
44. Manzanares, P. A. R., Isoardi, N. A., Carrer, H. F., and Molina, V. A. (2005). Previous stress facilitates fear memory, attenuates GABAergic inhibition, and increases synaptic plasticity in the rat basolateral amygdala. J. Neurosci. 25, 8725-8734.
45. Maren, S. (2000). Auditory fear conditioning increases CS-elicited spike firing in lateral amygdala neurons even after extensive overtraining. Eur. J. Neurosci. 12, 4047-4054.
46. Maren, S., and Quirk, G. J. (2004). Neuronal signalling of fear memory. Nat. Rev. Neurosci. 5, 844-852.
47. Masand, P. S., and Gupta, S. (1999). Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatry 7, 69-84.
48. McKernan, M. G., and ShinnickGallagher, P. (1997). Fear conditioning induces a lasting potentiation of synaptic currents in vitro. Nature 390, 607-611.
49. McKie, S., Del-Ben, C., Elliott, R., Williams, S., Del Vai, N., Anderson, I., and Deakin, J. F. W. (2005). Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl.) 180, 680-686.
50. Mir, S., and Taylor, D. (1997). The adverse effects of antidepressants. Curr. Opin. Psychitary 10, 88-94.
51. Mitra, R., Jadhav, S., Mcewen, B. S., Vyas, A., and Chattarji, S. (2005). Stress duration modulates the spatiotemporal patterns of spine formation in the basolateral amygdala. Proc. Natl. Acad. Sci. U.S.A. 102, 9371-9376.
52. Mukherjee, J., Das, M. K., Yang, Z. Y., and Lew, R. (1998). Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study. Nucl. Med. Biol. 25, 605-610.
53. Norman, E. D., Egli, R. E., Colbran, R. J., and Winder, D. G. (2005). A potassium channel blocker induces a long-lasting enhancement of corticostriatal responses. Neuropharmacology 48, 311-321.
54. Pare, D., Quirk, G. J., and Ledoux, J. E. (2004). New vistas on amygdala networks in conditioned fear. J. Neurophysiol. 92, 1-9.
55. Quirk, G. J., Repa, C., and Ledoux, J. E. (1995). Fear conditioning enhances short-latency auditory responses of lateral amygdala neurons: parallel recordings in the freely behaving rat. Neuron 15, 1029-1039.
56. Rainnie, D. G. (1999). Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J. Neurophysiol. 82, 69-85.
57. Rainnie, D. G., Bergeron, R., Sajdyk, T. J., Patil, M., Gehlert, D. R., and Shekhar, A. (2004). Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J. Neurosci. 24, 3471-3479.
58. Reznikov, L. R., Grillo, C. A., Piroli, G. G., Pasumarthi, R. K., Reagan, L. P., and Fadel, J. (2007). Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: differential effects of antidepressant treatment. Eur. J. Neurosci. 25, 3109-3114.
59. Rogan, M. T., Staubli, U. V., and Ledoux, J. E. (1997). Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390, 604-607.
60. Roozendaal, B., Mcewen, B. S., and Chattarji, S. (2009). Stress, memory and the amygdala. Nat. Rev. Neurosci. 10, 423-433.
61. Salchner, P., and Singewald, N. (2002). Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43, 1238-1248.
62. Salchner, P., and Singewald, N. (2006). 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology (Berl.) 185, 282-288.
63. Sanchez, C., and Meier, E. (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression-are they all alike? Psychopharmacology (Berl.) 129, 197-205.
64. Shankaranarayana Rao, B. S., and Raju, T. R. (2004). "The golgi techniques for staining neurons, " in Brain and Behavior, eds T. R. Raju, B. M. Kutty, T. N. Sathyaprabha, and B. S. Shankaranarayana Rao (Bangalore: National Institute of Mental Health and Neurosciences), 108-111.
65. Sheehan, D. V., Raj, B. A., Trehan, R. R., and Knapp, E. L. (1993). Serotonin in panic disorder and social phobia International Clinical. Psychopharmacology (Berl.) 8, 63-77.
66. Silva, R. C. B., and Brandao, M. L. (2000). Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol. Biochem. Behav. 65, 209-216.
67. Singewald, N., Salchner, P., and Sharp, T. (2003). Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry 53, 275-283.
68. Spigset, O. (1999). Adverse reactions of selective serotonin reuptake inhibitors-reports from a spontaneous reporting system. Drug Saf. 20, 277-287.
69. Stahl, S. M. (2000). Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol. Psychiatry 48, 894-901.
70. Stokes, P. E., and Holtz, A. (1997). Fluoxetine tenth anniversary update: the progress continues. Clin. Ther. 19, 1135-1250.
71. Stutzmann, G. E., and Ledoux, J. E. (1999). GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J. Neurosci. 19, RC8.
72. Stutzmann, G. E., Mcewen, B. S., and Ledoux, J. E. (1998). Serotonin modulation of sensory inputs to the lateral amygdala: dependency on corticosterone. J. Neurosci. 18, 9529-9538.
73. Teicher, M. H., Glod, C., and Cole, J. O. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry 147, 207-210.
74. Trommald, M., and Hulleberg, G. (1997). Dimensions and density of dendritic spines from rat dentate granule cells based on reconstructions from serial electron micrographs. J. Comp. Neurol. 377, 15-28.
75. Trommald, M., Jensen, V., and Andersen, P. (1995). Analysis of dendritic spines in rat CA1 pyramidal cells intracellularly filled with a fluorescent dye. J. Comp. Neurol. 353, 260-274.
76. van der Kolk, B. A., Dreyfuss, D., Michaels, M., Shera, D., Berkowitz, R., Fisler, R., and Saxe, G. (1994). Fluoxetine in posttraumatic stress disorder. J. Clin. Psychiatry 55, 517-522.
77. Vyas, A., Mitra, R., Rao, B. S. S., and Chattarji, S. (2002). Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J. Neurosci. 22, 6810-6818.